Neuphoria Therapeutics Inc
neuphoriatx.comWhat Do They Do?
Licenses drug-development rights to pharmaceutical and biotechnology partners and maintains a candidate for post-traumatic stress disorder.
10-K for FY2026, filed Sep 18, 2026In November 2020, we exclusively licensed certain BNC101 intellectual property to Carina Biotech for the development of CAR-T and other…View ↗
In June 2014, we entered into a research collaboration and license agreement with Merck to develop alpha7 receptor positive allosteric…View ↗
We did not initiate the planned SYMPHONY Phase 2b/3 trial. The PTSD program maintains clinical readiness, and any future development would…View ↗
How Do They Make Money?
The company receives CTx CRC distributions when its contractual right to proceeds from licensed technologies is established. Merck and Carina may also pay development milestones and royalties tied to sales of licensed medicines.
10-K for FY2026, filed Sep 18, 2026Beginning in 2016, the CRC became self-funding through licensing and commercialization activities with third-party customers. The CRC…View ↗
The Company recognizes CRC distributions when its contractual right to receive the distribution becomes fixed or determinable and…View ↗
On March 19, 2025, the Company received a $15 million milestone payment from Merck. The payment was triggered by the initiation by Merck of…View ↗
Regulatory milestone payments are triggered upon the achievement of certain research and commercial milestones. The commercial milestone…View ↗
In November 2020, the Company entered into an IP license agreement (the “Carina Biotech License”) with Carina Biotech Pty Ltd ("Carina…View ↗
$1.2M
-
10-K for FY2026, filed Sep 18, 2026
$1.2M ↗
Who Are Their Customers?
Pharmaceutical and biotechnology companies license drug-development rights directly from Neuphoria or through the CTx CRC; Merck and Carina hold Neuphoria licenses, while Pfizer controls the KAT6 program licensed through the CRC.
10-K for FY2026, filed Sep 18, 2026In June 2014, we entered into a research collaboration and license agreement with Merck to develop alpha7 receptor positive allosteric…View ↗
In November 2020, we exclusively licensed certain BNC101 intellectual property to Carina Biotech for the development of CAR-T and other…View ↗
We participated in the former CTx CRC, which commercialized drug-discovery projects on behalf of its participants. Pfizer licensed a KAT6…View ↗
Beginning in 2016, the CRC became self-funding through licensing and commercialization activities with third-party customers. The CRC…View ↗
Do Revenues Turn Into Profits?
No. It lost $13.5M in FY2026.
10-K for FY2026, filed Sep 18, 2026
Loading...
